114. Why Reflow Medical’s Spur System Is Changing BTK Treatment

This week’s episode features Dr. Anahita Dua, MD, MBA, Associate Professor of Surgery at Massachusetts General Hospital and Harvard Medical School, and Director of the Peripheral Artery Disease Center at MGH. She joins us for a detailed conversation on below-the-knee disease, why recoil after POBA remains a real limitation, and how a retrievable stent platform like Reflow Medical's Spur System is designed to disrupt plaque in a controlled way without leaving a permanent implant. Dr. Dua walks through the clinical rationale behind plaque modification, drug penetration, durability data from early studies through FDA clearance, and how she evaluates outcomes in her own patients through duplex follow-up and wound healing.This episode centers on Dr. Dua’s clinical perspective on tibial interventions and how newer device concepts are influencing real-world decision-making.03:35 The evolution of complex below-the-knee disease05:09 Why balloon angioplasty alone often leads to recoil24:44 FDA endpoints versus clinical durability25:41 Histologic plaque disruption and controlled microchannels28:16 Temporary scaffold concept and billing without leaving a stent30:27 Retrievable stent design and drug penetration strategy31:34 First-in-human experience and multicenter durability data33:12 Restenosis and the importance of long-term follow-up49:51 Duplex stability and wound healing as meaningful outcomes Who Should ListenVascular surgeons, interventionalists, PAD-focused clinicians, and MedTech leaders who are evaluating durability, restenosis, and how device design translates into real-world outcomes.About Dr. Anahita DuaDr. Anahita Dua is an Associate Professor of Surgery at Massachusetts General Hospital and Harvard Medical School. She serves as Director of the Peripheral Artery Disease Center, Associate Director of the Wound Center, Clinical Director of Research, and Director of the Sub-Internship in Vascular Surgery. Dr. Dua completed her vascular surgery fellowship at Stanford University Hospital, general surgery residency at the Medical College of Wisconsin, and her medical school in the United Kingdom. She has also completed a master's degree (MS) in trauma sciences and a master's in business administration (MBA) in health care management.Dr. Dua is double board-certified in vascular surgery and general surgery. She is also boarded in advanced wound care and management.Connect with Dr. Anahita💼 LinkedIn: Anahita DuaAbout Reflow Medical Inc.Reflow Medical, Inc. is a privately held medical device company based in San Clemente, California, and a leading developer of innovative medical devices focused on complex cardiovascular disease.A core element of Reflow Medical’s approach is the close collaboration between physicians and engineers, enabling rapid iteration from clinical insight to device design and real-world application.The company’s portfolio includes coronary and peripheral microcatheters, crossing catheters, and the Spur® Stent System, which enables Retrievable Scaffold Therapy (RST), a temporary scaffolding approach designed to modify lesions, reduce recoil, and leave nothing behind.Reflow Medical is committed to improving endovascular therapy outcomes for patients with complex lesions through clinically driven innovation.Learn more about Reflow Medical 🌐 Website: reflowmedical.com/💙 Spur: reflowmedical.com/spur/Follow Life of Flow📲 Instagram: @LifeofFlowPodcast👍 Facebook: Life of Flow Podcast💼 LinkedIn: Life of Flow Podcast🐦 X: @VascularPodcastIf this episode clarified how you think about below-the-knee disease and durability, share it with a colleague who would value the discussion. And if you’re enjoying Life of Flow, a quick review helps other physicians find conversations like this.